Efficacy of Apremilast in Patients with Psoriasis with Limited Skin Involvement, Including High-Impact Site Involvement: A Pooled Analysis of Six Trials - Scorecard - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Effectiveness of Apremilast in Individuals with Psoriasis Exhibiting Minimal Skin Involvement and High-Impact Area Affected: A Combined Analysis of Six Clinical Trials

  • By

  • Bruce Strober

  • Mark Lebwohl

  • Peter van de Kerkhof

  • Linda Stein Gold

  • Joseph F. Merola

  • Yukari Okubo

  • Paolo Gisondi

  • Zhenwei Zhou

  • Siddharth Chaudhari

  • Cynthia Deignan

  • Ulrich Mrowietz

  • October 2, 2026

Share

Clinical Scorecard: Effectiveness of Apremilast in Individuals with Psoriasis Exhibiting Minimal Skin Involvement and High-Impact Area Affected: A Combined Analysis of Six Clinical Trials

At a Glance

CategoryDetail
ConditionPlaque Psoriasis
Key MechanismsApremilast is an oral phosphodiesterase 4 inhibitor that improves cutaneous symptoms and quality of life.
Target PopulationAdults with plaque psoriasis and affected body surface area of 3–10%, including high-impact sites.
Care SettingClinical trials evaluating systemic treatment options.

Key Highlights

  • Apremilast enhances skin clearance and quality of life by week 16.
  • Benefits are sustained through week 32.
  • Effective for patients with limited skin involvement and high-impact site symptoms.

Guideline-Based Recommendations

Diagnosis

  • Diagnosis of plaque psoriasis with affected body surface area of 3–10%.

Management

  • Consider systemic therapy for patients with high-impact site involvement.

Monitoring & Follow-up

  • Evaluate skin clearance and quality of life improvements at weeks 16 and 32.

Risks

  • Limited treatment options for patients with minimal skin involvement.

Patient & Prescribing Data

Patients with plaque psoriasis and limited skin involvement (BSA 3–10%).

Apremilast is supported as a systemic option for this population.

Clinical Best Practices

  • Utilize apremilast for patients with high-impact site involvement.
  • Monitor patient outcomes at specified intervals to assess treatment efficacy.

Related Resources & Content

Original Source(s)

Efficacy of Apremilast in Patients with Psoriasis with Limited Skin Involvement, Including High-Impact Site Involvement: A Pooled Analysis of Six Trials

  • by Bruce Strober, Mark Lebwohl, Peter van de Kerkhof, Linda Stein Gold, Joseph F. Merola, Yukari Okubo, Paolo Gisondi, Zhenwei Zhou, Siddharth Chaudhari, Cynthia Deignan, Ulrich Mrowietz

  • October 2, 2026

Related Content

FDA Expands Guselkumab Label in PsA

Phase 3b APEX findings support the addition of structural joint damage inhibition data to the prescribing information.

The Circadian Skin: Chronobiology as a New Frontier in Dermatological Therapy

Matching-Adjusted Indirect Comparison of Risankizumab Versus Icotrokinra in Adult Patients with Moderate-to-Severe Plaque Psoriasis